Dark

OXFD
Oxford Immunotec Global PLC
stock NASDAQ

Inactive

Mar 5, 2021

21.99USD+0.045%(+0.01)808,562

Pre-market

0.00USD-100.000%(-21.98)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Mar 4, 2021

02:29PM EST Oxford Immunotec Submits Emergency Use Authorization Request To FDA And CE Marks T-SPOT COVID Test For Detection Of A Cell Mediated Immune Response To COVID-19 Infection Benzinga

02:27PM EST Marks T-SPOT(r).COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection PR Newswire

Feb 17, 2021

01:22PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on PR Newswire

Feb 10, 2021

12:03AM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates CUB, CRHM, GLUU, OXFD, OBLN; PR Newswire

Feb 9, 2021

03:29PM EST Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD PR Newswire

Feb 8, 2021

09:18AM EST Oxford Immunotec Reports Deal With Green Cross Medical Science To Market T-SPOT Discovery SARS-CoV-2 Kit For Measurement Of T Cell Immune Response To Infection In South Korea Benzinga

09:15AM EST Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. GlobeNewswire Inc

Feb 7, 2021

08:01AM EST Lifshitz Law Firm, P.C. Announces Investigation of CHNG, CPAH, HMSY, INFO, PR Newswire

Feb 4, 2021

09:15AM EST Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit, for research use only, has been updated using the Companys growing expertise of the T cell response to SARS-CoV-2 infection. GlobeNewswire Inc

Jan 30, 2021

05:03PM EST Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders PR Newswire

Jan 29, 2021

10:02AM EST Magnetar Financial Reports In 13D Filing A 7.75% Active Stake In Oxford Immunotec Global PLC Benzinga

Jan 25, 2021

12:12PM EST Moore Kuehn Encourages PROS, JWS, OXFD, and CIIC Investors to Contact Law Firm PR Newswire

Jan 24, 2021

11:08AM EST Lifshitz Law Firm, P.C. Announces Investigation of CHNG, COHR, LITE, CPAH, PR Newswire

Jan 22, 2021

11:44AM EST ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of PR Newswire

Jan 21, 2021

03:29PM EST SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PR Newswire

03:09PM EST Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: GlobeNewswire Inc

Jan 20, 2021

06:03PM EST SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GlobeNewswire Inc

Jan 14, 2021

04:41PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates BPFH, OXFD, PNM, ANH, XLNX, PR Newswire

09:15AM EST Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company, announces the launch of 100 Physicians Find, a monthly survey that takes the pulse of one hundred medical professionals on the front lines of the COVID-19 pandemic about their perspectives, experiences and needs in the face of this global health crisis. GlobeNewswire Inc

Jan 13, 2021

07:20PM EST OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD Business Wire

09:19AM EST Oxford Immunotec Reports Its T-SPOT Discovery SARS-CoV-2 Test Is Used To Measure Efficacy Of Valneva's VLA2001 COVID-19 Vaccine Candidate In Phase 1/2 Study Benzinga

09:15AM EST Oxford Immunotecs T-SPOT Discovery GlobeNewswire Inc

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 7, 2021

11:12AM EST Piper Sandler Downgrades Oxford Immunotec Global to Neutral, Lowers Price Target to $22 Benzinga

07:16AM EST PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company's entire issued and to be issued ordinary share capital at approximately $591 million. RTTNews

07:05AM EST PerkinElmer To Acquire Oxford Immunotec RTTNews

07:01AM EST PerkinElmer to Acquire Oxford Immunotec Global PLC For $22/Share In Cash Benzinga

07:00AM EST PerkinElmer to Acquire Oxford Immunotec Global PLC Business Wire

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 16, 2020

09:15AM EST Oxford Immunotec Announces the Foundation of the Global T Cell GlobeNewswire Inc

Dec 10, 2020

09:15AM EST Oxford Immunotec Announces Approval Of T-Cell Select Reagent Kit, Used To Automate The T-SPOT.TB Test Workflow, for IVD Use in South Korea Benzinga

09:15AM EST Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company today announced that the Companys T-Cell Select reagent kit has been approved for use by the Ministry of Food and Drug Safety, South Korea. GlobeNewswire Inc

Dec 2, 2020

09:10AM EST Oxford Immunotec Signs Exclusive Distributor Agreement With RIKEN Genesis To Market T-SPOT Discovery SARS-CoV-2 Kit RTTNews

09:00AM EST Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. GlobeNewswire Inc

Nov 23, 2020

07:30AM EST Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020 GlobeNewswire Inc

Nov 10, 2020

09:22AM EST Oxford Immunotec Highlights Data Showing SARS-CoV-2 Reactive T Cells Are Associated With Protection From COVID-19, Can Be Detected, Measured Using Co.'s Immunotec T-SPOT Technology Benzinga

09:00AM EST Data Showing SARS-CoV-2 Reactive T Cells are Associated with GlobeNewswire Inc

Nov 5, 2020

09:06AM EST Oxford Immunotec Files Submission To FDA For T-Cell Select Reagent Kit Benzinga

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

07:05AM EST Oxford Immunotec Global Q3 Sales $19.40M Beat $18.65M Estimate Benzinga

07:00AM EST Oxford Immunotec Reports Third Quarter 2020 Financial Results GlobeNewswire Inc

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

05:30AM EDT UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole GlobeNewswire Inc

05:23AM EDT Britain to Partner with Oxford Immunotec to Assess Coronavirus Vaccine T cell Responses Benzinga

05:23AM EDT Britain to Partner with Oxford Immunotec Firm to Assess Coronavirus Vaccine T cell Responses Benzinga

05:22AM EDT Britain to Partner with Oxford Firm to Assess Coronavirus Vaccine T cell Responses Benzinga

Oct 21, 2020

04:05PM EDT Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and GlobeNewswire Inc

Sep 29, 2020

09:02AM EDT Oxford Immunotec Announces FDA Clearance Of T-SPOT TB Test For Use In Pediatrics Over The Age Of Two Benzinga

09:00AM EDT Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced that it has received clearance from the FDA to amend the pediatric age limitation to allow use of the T-SPOT.TB test in individuals two years of age and older. GlobeNewswire Inc

Sep 22, 2020

09:04AM EDT Oxford Immunotec Joins Forces With Public Health England In Large Clinical Trial Utilizing T-Spot Discovery Coronavirus Test Benzinga

09:00AM EDT Oxford Immunotec Joins Forces with Public Health England (PHE) in GlobeNewswire Inc

Aug 4, 2020

07:41AM EDT Oxford Immunotec Sees Q3 Sales $18M-$19M vs $15M Estimate Benzinga

07:40AM EDT Oxford Immunotec Global Q2 EPS $(0.37) Misses $(0.30) Estimate, Sales $5.83M Beat $5.80M Estimate Benzinga

07:00AM EDT -- Second quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 -- Ended the quarter with approximately $165 million of cash and cash equivalents -- Third quarter revenue estimated to be between $18 - $19 million GlobeNewswire Inc

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 21, 2020

09:15AM EDT Oxford Immunotec Schedules Second Quarter 2020 Earnings Release GlobeNewswire Inc

Jul 20, 2020

09:17AM EDT Oxford Immunotec Announces Agreement With Stop TB Partnership Benzinga

09:15AM EDT Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-term agreement to supply its T-SPOT.TB test and associated accessories to the Stop TB Partnership - Global Drug Facility (GDF). This follows the inclusion of the T-SPOT.TB test in the GDFs diagnostics catalog for the detection of tuberculosis (TB) infection. GlobeNewswire Inc